Kumar Neil sold $691K of BBIO (indirect holdings)

Kumar Neil (Chief Executive Officer) sold 10,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $69.08 ($69.01–$69.57, $0.69M total) across 2 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Sep 21, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, likely limiting market reaction.

02

Market read

Provides a fresh data point for traders tracking insider activity, but limited actionable impact.

03

What to watch

CEO's 10b5-1 plan may be unrelated to company fundamentals.

Relevance 4/10Novelty 4/10Timing: post filing 2026-09-21

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

CEO Kumar Neil sold $691K of BBIO shares via a 10b5-1 plan on 2026-09-17.

Expected impact

Potential short-term dip of 1-2% if market reacts.

Evidence & confidence

Insider sales often cause slight negative sentiment; however, the transaction is pre‑arranged and modest in scale.

Market effects

Minimal impact on biotech sector; similar insider sales are common.

No regional effect beyond BBIO's trading venue.

Negligible on a global scale.

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • BridgeBio Pharma, Inc.

    Biotech firm listed on NASDAQ under BBIO.

  • Kumar Neil

    CEO and Director of BridgeBio Pharma.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.